Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01095887 · ClinicalTrials.gov registry record · Phase 1
Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01095887: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT01095887 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01095887, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to try to determine if the drug eculizumab can help prevent antibody-mediated rejection in patients undergoing a kidney transplant from a living donor with a different blood type than their own.
Interventions
- DRUG Eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-05 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01095887
The ClinicalTrials.gov registry entry for NCT01095887 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eculizumab is the first listed.
NCT01095887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01095887 about?
NCT01095887 is a clinical study titled "Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation". The purpose of this study is to try to determine if the drug eculizumab can help prevent antibody-mediated rejection in patients undergoing a kidney transplant from a living donor with a different blood type than their own.
What is the current status of trial NCT01095887?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2010-05. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01095887?
The interventions under investigation include: Eculizumab (DRUG).
Who is sponsoring clinical trial NCT01095887?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.